As consumers continue to lean into self-care and wellness trends, the nail care industry is expanding, with a 2024 global market value of $8.8 billion that is forecasted to keep
The official launch of Le-Vel’s exosome-based skin system, XERA, on Dec. 16 marks what the company describes as a new era in skin repair, restoration, and renewal. “XERA represents a
Conexeu Sciences Inc. has reported a milestone in regenerative medicine with the creation of the first 3D-printed tissue structures from its patented functional extracellular matrix (ECM). While the company is
A new study led by Northwestern Medicine and the University of California, San Francisco offers compelling evidence that tanning beds mutate skin cells far beyond the effects of ordinary sunlight
The U.S. Food and Drug Administration (FDA) has proposed adding bemotrizinol to its list of permitted active ingredients for use in sunscreens — marking the agency’s first potential addition of
The future of Artificial Intelligence (AI) in dermatology is being explored with a mixture of confidence and caution. AI shows promise for improving patient-clinician interactions and supporting personalized care in
A significant breakthrough in understanding the causes of hypersensitivity in sensitive skin was presented at the 50th Convention of the Japanese Cosmetic Science Society. Researchers from the Kao Company highlighted
The recent passage of the SAFE Sunscreen Standards Act (H.R. 3686/S. 2491), which modernizes how the U.S. Food and Drug Administration (FDA) reviews and approves sunscreen ingredients, marks an important advancement
Chronic spontaneous urticaria impacts roughly 1.7 million people in the United States, underscoring the need for improved therapies. Data presented at the American College of Allergy, Asthma & Immunology Annual
The U.S. Food and Drug Administration (FDA) recently approved Restylane Lyft with Lidocaine for augmentation of the chin region to improve the chin profile in patients aged 21 and older
In a recent safety communication, the U.S. Food and Drug Administration (FDA) issued a warning to consumers, patients, and health care providers about serious complications reported in connection with certain
As dermatology continues to embrace diversity and inclusivity, increasing attention is being paid to the unique needs of patients with skin of color. A recent reanalysis of a study in
The FDA has approved adalimumab-aaty (YUFLYMA; Celltrion, Inc.) for the treatment of adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV) in the U.S. This approval, which covers both YUFLYMA and
The FDA has approved cemiplimab-rwlc (Libtayo; Regeneron Pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk for recurrence following surgery and radiation. This
The FDA has approved roflumilast (Zoryve, Arcutis), a once-daily, steroid-free cream for the topical treatment of mild-to-moderate atopic dermatitis (AD) in children aged 2 to 5 years. This approval marks
The FDA recently approved remibrutinib (Rhapsido, Novartis), the first and only oral, targeted Bruton’s tyrosine kinase inhibitor (BTKi) for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite
Atopic dermatitis (AD) remains the most common chronic inflammatory skin condition, with persistent itch, barrier dysfunction, and inflammation continuing to drive significant disease burden. These ongoing challenges highlight the critical
A new, large-scale study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 has revealed a significant association between atopic eczema (AE) and suicidal ideation in adults.
Two recent clinical trial updates highlight the growing momentum of OX40-targeted therapies for atopic dermatitis (AD), underscoring an emerging strategy for long-term disease control. Sanofi’s Amlitelimab Sanofi recently announced positive
Arcutis Biotherapeutics recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
